openPR Logo
Press release

Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | GW Pharmaceuticals plc, Zynerba Pharmaceuticals, InMed Pharmaceuticals, Echo Pharmaceuticals, Cara Therapeutics

04-25-2019 11:42 AM CET | Health & Medicine

Press release from: Cannabinoids Therapeutics-Pharma Proff

Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical

Cannabinoid is a type of alkaloid that is obtained from the cannabis sativaplants. Cannabis, also known as marijuana, produce resin containing compounds known as cannabinoids. Cannabinoids are being used for medical purposes from the ancient times. These are the active substance in Cannabis plants that produce pharmacological actions in the body that mostly involves central nervous system and immune system. Delta-9-THC (tetrahydrocannabinol) is the main active component of cannabinoids.

Download the sample report at: https://www.pharmaproff.com/request-customization/1181

Cannabinoids are being used for the pain relief, anxiety, nausea, vomiting, and loss of appetite. The compounds have shown beneficial effects in improving symptoms of cancer as well. Dronabinol and nabilone are approved drugs by the U.S. Food and Drug Administration (USFDA) for the treatment of chemotherapy induced nausea and vomiting. Dronabinol is also approved for anorexia associated with weight loss in patients with AIDS.

Get the detailed analysis at: https://www.pharmaproff.com/report/cannabinoids-therapeutics

Several pharmacological actions of cannabinoids are discovered in the laboratory, including anti-viral activity, blocking cell growth, anti-inflammation, and relieving muscle spasm caused by multiple sclerosis. Cannabis can be administered orally or via inhalation route. When taken by mouth, liver processes it and produces an additional psychoactive chemical.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1181

GW Pharmaceuticals plc is developing Epidiolex cannabinoid receptor CB1 antagonist for the treatment of Dravet syndrome, Rett syndrome, tuberous sclerosis complex, epilepsy and Lennox-Gastaut syndrome. The company is also developing Sativex, an oromucosal spray of a formulated extract of the cannabis sativa plant for the treatment of multiple sclerosis spasticity, neuropathic pain, and other neurological conditions. Zynerba Pharmaceuticals Inc. is developing ZYN002 as a cannabinoid receptor CB1 antagonist for the treatment of fragile X syndrome, epilepsy, and autism spectrum disorder. InMed Pharmaceuticals Inc. is developing INM-750 as a gene expression modulator for the treatment of epidermolysis bullosa. Other than this Echo Pharmaceuticals Inc. and Cara Therapeutics Inc. are also involved in the pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | GW Pharmaceuticals plc, Zynerba Pharmaceuticals, InMed Pharmaceuticals, Echo Pharmaceuticals, Cara Therapeutics here

News-ID: 1717860 • Views: 1092

More Releases for Cannabinoid

Medicinal Cannabis Market to Show Strong Growth | Leading players Medlab Clinica …
The Latest survey report on Global Medicinal Cannabis Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Medicinal Cannabis organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medlab Clinical, Oxford Cannabinoid Technologies, GW Pharmaceuticals, Botanix Pharmaceuticals, MGC Pharmaceuticals, Queensland
Global Synthetic Cannabinoid Market Growth Data Analysis 2020-2025
Market Overview The Synthetic Cannabinoid market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations. The global Synthetic Cannabinoid market size is expected to gain market growth in the forecast period of 2020 to 2025, with
Synthetic Cannabinoid Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Synthetic Cannabinoid market analysis, which studies the Synthetic Cannabinoid's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “Synthetic Cannabinoid Market 2020-2025” Research Report categorizes the global Synthetic Cannabinoid market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
Cannabinoid Therapy Market Greater Revenue Share by 2027(Based on therapy type, …
A cannabinoid is a class of chemical compounds that change the neurotransmitter release in the brain by acting on cannabinoid receptors in the cells. Cannabinoids are derived from plants and are also referred to as the phytocannabinoids. Majority of the cannabinoids available for cannabinoid therapy are cannabis-driven, but there are several different plants from which cannabinoids can be derived as well. Approximately 70 plant compounds are identified for cannabinoids. Majority
Cannabinoid Therapy Market Value Chain, Dynamics and Key Players 2018 to 2027(Ba …
A cannabinoid is a class of chemical compounds that change the neurotransmitter release in the brain by acting on cannabinoid receptors in the cells. Cannabinoids are derived from plants and are also referred to as the phytocannabinoids. Majority of the cannabinoids available for cannabinoid therapy are cannabis-driven, but there are several different plants from which cannabinoids can be derived as well. Approximately 70 plant compounds are identified for cannabinoids. Majority
Cannabinoid Therapy Market Future Forecast Indicates Impressive Growth Rate(Base …
A cannabinoid is a class of chemical compounds that change the neurotransmitter release in the brain by acting on cannabinoid receptors in the cells. Cannabinoids are derived from plants and are also referred to as the phytocannabinoids. Majority of the cannabinoids available for cannabinoid therapy are cannabis-driven, but there are several different plants from which cannabinoids can be derived as well. Approximately 70 plant compounds are identified for cannabinoids. Majority